Brokerages Set Charles River Laboratories International, Inc. (NYSE:CRL) PT at $214.00

Charles River Laboratories International, Inc. (NYSE:CRL) has received an average rating of “Reduce” from the fifteen ratings firms that are covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $214.00.

A number of equities research analysts have issued reports on the stock. StockNews.com downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. Citigroup downgraded Charles River Laboratories International from a “neutral” rating to a “sell” rating and decreased their price target for the company from $215.00 to $175.00 in a research report on Tuesday, October 1st. Redburn Atlantic started coverage on Charles River Laboratories International in a report on Monday, October 14th. They set a “sell” rating and a $151.00 price target on the stock. Evercore ISI upped their price objective on Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research note on Thursday, November 7th. Finally, UBS Group boosted their price target on shares of Charles River Laboratories International from $240.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, November 7th.

Charles River Laboratories International Stock Up 0.5 %

CRL stock opened at $186.29 on Thursday. The firm has a market capitalization of $9.53 billion, a PE ratio of 23.32, a P/E/G ratio of 5.00 and a beta of 1.38. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. Charles River Laboratories International has a twelve month low of $176.48 and a twelve month high of $275.00. The stock’s 50 day moving average is $193.52 and its 200-day moving average is $201.53.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The business had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $975.99 million. During the same period last year, the business earned $2.72 EPS. The business’s revenue was down 1.6% on a year-over-year basis. Sell-side analysts expect that Charles River Laboratories International will post 10.18 EPS for the current fiscal year.

Insider Activity at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the transaction, the director now directly owns 12,386 shares in the company, valued at approximately $2,676,862.32. The trade was a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new stake in shares of Charles River Laboratories International during the third quarter valued at about $601,000. State Street Corp grew its stake in Charles River Laboratories International by 2.0% during the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock valued at $419,601,000 after acquiring an additional 41,421 shares in the last quarter. Quest Partners LLC increased its holdings in Charles River Laboratories International by 135,175.0% during the 2nd quarter. Quest Partners LLC now owns 5,411 shares of the medical research company’s stock worth $1,118,000 after acquiring an additional 5,407 shares during the period. Neo Ivy Capital Management purchased a new stake in Charles River Laboratories International in the 3rd quarter worth approximately $966,000. Finally, Janus Henderson Group PLC boosted its holdings in Charles River Laboratories International by 7.6% in the 3rd quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company’s stock valued at $9,064,000 after purchasing an additional 3,268 shares during the period. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).